## Quality Affordable Healthcare Products<sup>™</sup> Since 1887

# William Blair Growth Stock Conference






Certain statements in this presentation are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



# **Portfolio of Leading Store Brands & Generics** FY2012 Portfolio by Sales (\$3.17B)








Quality Affordable Healthcare Products™

4

Perrigo Consolidated – Key Financial Performance\*



Revenue CAGR of 16% 4 Year Adjusted Operating Income CAGR of 30%

4 Year


4 Year Operating Cash Flow CAGR of 19%





5 \*See attached financial schedule for reconciliation to GAAP numbers






# 7 Year Organic CAGR of 9%

7 Year Inorganic CAGR of 44%




\*Organic sales exclude the effects of acquisitions; acquisitions and their subsequent growth remain in inorganic sales in years following the acquisition

# One of the World's Leading Pharmaceutical Manufacturers





**Consumer Healthcare Segment\*** Leveraging the Perrigo Advantage





Consumer Healthcare

8








\$57.27	Cost to Retailer	\$23.50
\$71.59	Retail Selling Price	\$52.99
\$14.32	\$ Profit	\$29.49
20%	% Profit	56%
	Consumer Savings	26%

**Big Dollar Profits and Margin for Retailers** 

**Reason for Large Investments by Retailers in Store Brands** 









\*Vitamins, Minerals, and Supplements

10 Source: IRI 52 Week Data through April 7, 2013; FDMx

# Power of Perrigo – Recent Product Launches


#### **Cetirizine**





Allergy Rejet


#### With over 7 OTC approvals, Perrigo has 80% Store Brand Market Share






# <section-header>

With 5 OTC approvals, Perrigo has >85% Store Brand Market Share














Consumer Healthcare



We expect the switch of Allegra<sup>®</sup> from Rx to OTC will increase the size of the category, while having minimal impact to other NSA products

Every major NSA switch increased the OTC Allergy market over 50%!

**OTC \$ Market** 



Company and Consumer Healthcare Growth – FY13 & Beyond

Publicly disclosed products

Across ALL segments, we expect to launch >60 new products, resulting in ~\$130M of revenue in FY 2013

#### Potential Rx to OTC switches

• \$10B in branded sales potential over the next 5 years



Consumer Healthcare

OTC Potential Future Product Pipeline


Future Pipeline		Brand Sales (\$B)
Nexium ®	Esomeprazole (Rx)	\$ 7.6
Protonix ®	Pantoprazole (Rx)	3.2
Aciphex ®	Rabeprazole (Rx)	1.1
Mucinex ® Family	Guaifenesin RS, D, RS D, RS DM, MAX, MAX DM	0.7
Nasonex ®	Triamcinolone Acetonide	0.4
Clarinex ®	Desloratadine (Rx)	0.3
Plan B One- Step®	Levonorgestrel	0.4
Voltaren ®	Diclofenac Topical Gel	0.2
Advil ® LG	Ibuprofen LG	0.2
Allegra ® D 12	Fexofenadine D12 (Rx)	0.1
Allegra ® D 24	Fexofenadine D24 (Rx)	0.1
Zegerid ®	Omeprazole Sodium Bicarbonate	0.1
<u>Oxytrol ®</u>	<u>Oxybutynin Transdermal (Rx)</u>	<u>0.1</u>
Total		\$ 14.5

Potential Switch Products/Categories	Bra	nd Sales (\$B)
Statins	\$	17.0
Singulair ®		5.3
Prostate		3.6
Cox-2 Inhibitors		3.5
Erectile Dysfunction		2.9
Nasal Allergy		2.5
Overactive Bladder		2.2
Migraine		1.7
Omega-3 Fish Oils		1.6
Ophthalmic-Allergy/Dry Eye		1.3
Acne		0.6
Total	\$	42.2




**\$73B in Potential Switch Product Categories (\$M)** 

Excluding \$42B on Slide 15



Consumer Healthcare

# Opportunities to Expand Our Business Through Adjacent Categories (\$B)



Consumer Healthcare

# Pet Care Overview – Large & Growing Market Combined Sergeant's & Velcera Acquisitions

#### **Strategic Fit**

- Flea & Tick category ~\$1.6 billion retail sales market
- Adds PetArmor® and Sergeant's brands to become the #1
  flea & tick value-brand franchises
- Adds PetTrust<sup>™</sup> Plus brand contains the same active ingredients as the #1 veterinarian-recommended heartworm preventive
- Ability to leverage distribution and add products into established Store Brand infrastructure
- Provides in-house manufacturing capabilities

#### **Financially Attractive**

- Adds ~\$200 million in annual sales
- Expected to be at least \$0.31 accretive to adjusted EPS and ~\$0.13 accretive to GAAP EPS in FY 2014<sup>(1)</sup>
- Sergeant's expected to be ROIC accretive in FY 2014 and Velcera in FY 2015
- Gross margins above and operating margins in-line with corporate average

#### **Transaction Details**

- \$445 million all cash transactions
- Financed entirely from cash on hand










Diabetes Care Overview – Large & Growing Market



Partnership with AgaMatrix to supply SB market with BGM testing supplies enabled us to target <u>>65% or \$3B</u> of the Diabetes Care Retail Segment

We are now the first COMPANY to have a presence in <u>100% or \$4.5B</u> of the Store Brand Diabetes Care Retail Segment


No other NB or SB offers the entire Diabetes Care product line today

Comprehensive, customized marketing initiatives to grow our Diabetes Care business, specifically targeting insulin users

- Placing our meters in the hands of insulin using patients
- Hypoglycemia, made with Dex4® fast acting glucose, marketing campaign focusing on taking market share from candy cola & juice categories



Nutritionals – Includes VMS\* and Infant Formula Leveraging the Perrigo Advantage



# Nutritionals Growth – FY13 & Beyond

Publicly disclosed products





#### **Plastic Infant Formula Tub**

- Upgrade to national brand style package
- Improved usage experience for parents
- Quality designed into manufacturing process
- Faster line speed increases plant capacity

#### **Chinese Formulas**

- Stage 3 with higher DHA
- Stage 4
- Prenatal / mothers formula
- Ultra-Premium Stage 1, 2 & 3

#### **CODEX Gold Formulas**

- Upgraded to include: prebiotics, lutein & DHA
- Targeting: Latin America, Africa & Middle East





Walma



**1947** Huggies<sup>®</sup> Pull Ups<sup>®</sup> Potty Training Starter Kit • Counts vary by size **13**<sup>27</sup> Parent's Choice™ Premium Infant Formula • 25.2 oz

**34**98 Enfamil<sup>®</sup> Premium or Gentlease Formula • 33.2-35 oz





Nutritionals

22

Store Brand Packaging Made to Match National Brand








#### **Store Brand Product Placement – Center, at Eye Level**





**Rx – Extended Topicals & Specialty Generics** Leveraging the Perrigo Advantage





Pharmaceuticals

25 \*See attached financial schedule for reconciliation to GAAP numbers



#### **35 ANDAs Pending FDA approval**

- ANDAs represent \$4B in branded sales
- 6 confirmed first-to-file ANDAs
- Additional 3 first-to-file ANDAs have final approval with later certain launch dates

#### **4** Paragraph IV litigations

- Repaglinide Tablets (Prandin<sup>®</sup>)
- Azelastine (Astepro<sup>®</sup>)
- Albuterol HFA Inhaler (Proair®)
- Testosterone 1.62% Gel (AndroGel® 1.62%)

#### **3 projects in clinical studies**

5		L	L
Rotes execution and the constraints of the constraints of the constrai	R COM R COM OF THE Relamethasone Relamethasone R Company of the R Company of th	excer to excert to Cobetasol Propionale Foam Emolijent Formilation) DUSO Mirrigad bio Only Mirrigad	ecce 40 2 Cobetasol Propionate Foar Emollient Formulation) 0.05% Intrapial Use Only. Intra optabalistic. Onl. Interreginal Use.
100 g Perrigo'	50g <u>Perrigo</u>	wg Perrigo	Rg Perrie

Rx FY13 Pipeline Highlights	Branded Sales (\$M)
Generic version Clobex® Shampoo	\$63 - Launched
Generic version of Luxiq® Foam	\$32 - Launched
Generic version of Olux-E® Foam	\$36 - Launched
>3 Other Undisclosed Products	>\$160





# Rx Growth – Leadership Position in Generic Foams

Publicly disclosed products

Cobrek acquisition solidifies leadership position in topical foambased technology

- 6 FDA approved topical foam-based products plus an additional ANDA for a topical generic product
- All cash transaction for approximately \$42 million
- Expected to be \$0.01 dilutive to GAAP and \$0.04 accretive to adjusted EPS in FY13
- Immediately accretive to ROIC hurdles

Clindamycin

Phosphate

Foam.



Rx Generic Foam Highlights	Launch Status
Clobetasol Propionate Foam, 0.05% (Olux®)	Launched
Clindamycin Phosphate Foam, 1% (Evoclin®)	Launched
Ketoconazole Foam, 2% (Extina®)	Launched
Betamethasone Valerate Foam, 0.12% (Luxiq®)	Launched
Clobetasol Propionate Foam, 0.05% (Olux-E®)	Launched

Ketoconazole

Foam.

2%

100 g





Perrigo





# **Rx Growth – Leadership Position in Oral Liquids** Rosemont Acquisition

#### **Strategic Fit**

- Solidifies leadership position in oral liquid formulations
- Expands international presence while further enhancing manufacturing and R&D capabilities
- >90 products vast majority are oral liquid generic products
- No product cliff most key products marketed for over a decade
- Balanced portfolio largest product represents <8% of sales

#### **Financially Attractive**

- Expected to be \$0.08 accretive to adjusted EPS for FY 2013 and ~\$0.04 to \$0.07 dilutive to GAAP EPS<sup>(1)</sup>
- Expected to be ~\$0.24 accretive to adjusted EPS and approximately neutral to GAAP EPS in the first 12 months postclosing
- Expected to be accretive to ROIC in FY 2015

#### **Transaction Details**

- ~£180 million or \$283 million all cash transaction
- Financed entirely from cash on hand



The source of liquid solutions.









API – Active Pharmaceutical Ingredients\*

Leveraging the Perrigo Advantage





PI



	FY 2013 Guidance 8/16/12 Conference Call	FY 2013 Guidance 11/7/12 Conference Call	FY 2013 Guidance 2/1/13 Conference Call	FY 2013 Guidance 2/11/13 Rosemont Acquisition	FY 2013 Guidance 5/7/13 Conference Call
CONSUMER HEALTHCARE Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	10% - 14% 30% - 35% 16% - 21%	16% - 20% 32% - 36% 17% - 21%	16% - 20% 32% - 36% 17% - 21%	16% - 20% 32% - 36% 17% - 21%	16% - 20% 32% - 36% 17% - 21%
<b>NUTRITIONALS</b> Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	8% - 12% 27% - 32% 12% - 17%	8% - 12% 27% - 32% 12% - 17%	1% - 5% 26% - 30% 10% - 14%	1% - 5% 26% - 30% 10% - 14%	1% - 5% 26% - 30% 10% - 14%
<b>RX PHARMACEUTICALS</b> Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	15% - 19% 54% - 59% 42% - 48%	15% - 19% 54% - 59% 42% - 48%	15% - 19% 54% - 59% 42% - 48%	15% - 19% 54% - 59% 42% - 48%	15% - 19% 54% - 59% 42% - 48%
<b>API</b> Revenue Growth Y/Y Adjusted Gross Margin % Adjusted Operating Margin %	0% - 4% 47% - 52% 27% - 32%	0% - 4% 47% - 52% 27% - 32%	0% - 4% 47% - 52% 27% - 32%	0% - 4% 47% - 52% 27% - 32%	0% - 4% 47% - 52% 27% - 32%



	FY 2013 Guidance				
	8/16/12 Conference	11/7/12 Conference	2/1/13 Conference	2/11/13 Rosemont	5/7/13 Conference
	Call	Call	Call	Acquisition	Call
CONSOLIDATED PERRIGO Revenue Growth Y/Y Adjusted Gross Margin % R&D as % to Net Sales Adjusted DSG&A as % to Net Sales Adjusted Operating Margin % Effective Tax Rate	10% - 14% 36% - 40% ~3.5% ~12.5% 20% - 24% 29% - 31%	12% - 16% 36% - 40% ~3.5% ~12.5% 21% - 24% 29% - 31%	12% - 16% 36% - 40% ~3.5% ~12.5% 21% - 24% 29% - 31%	12% - 16% 36% - 40% ~3.5% ~12.5% 21% - 24% 29% - 31%	12% - 16% 36% - 40% ~3.5% ~12.5% 21% - 24% 29% - 31%
Adjusted Diluted EPS	\$5.30 - \$5.50	\$5.45 - \$5.65	\$5.45 - \$5.65	\$5.53 - \$5.73	\$5.53 - \$5.73
Y/Y Growth	6% - 10%	9% - 13%	9% - 13%	11% - 15%	11% - 15%
Y/Y Growth w/out Discrete Tax <sup>†</sup>	13% - 17%	14% - 18%	14% - 18%	16% - 20%	16% - 20%
Operating Cash Flow	\$550M - \$575M				
CAPEX	\$110M - \$130M	\$120M - \$150M	\$120M - \$150M	\$120M - \$150M	\$110M - \$140M

† Implied	d Y/Y Growt	h Without Discrete	Tax Items Reconciliation
-----------	-------------	--------------------	--------------------------

	FY 2012	FY 2013 Guidance
Adjusted Diluted EPS	\$4.99	\$5.53 - \$5.73
Less: Discrete Tax Items	(0.28)	(0.08)
Adjusted Diluted EPS, Excluding Discrete Tax Items	\$4.71	\$5.45 - \$5.65
Implied FY Y/Y EPS Growth		11% - 15%
Implied FY Y/Y EPS Growth, Excluding Discrete Tax Items		16% - 20%

Legend:

Y/Y = Year over Year R&D = Research & Development Expense DSG&A = Distribution, Selling, General & Administrative Expense CAPEX = Capital Expenditures



# Appendix

Contacts:

Arthur J. Shannon, Vice President, Investor Relations and Communications (269) 686-1709 <u>ajshannon@perrigo.com</u> Bradley Joseph, Senior Manager, Investor Relations and Communications (269) 686-3373 <u>bradley.joseph@perrigo.com</u>





### Table I PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES (in thousands, except per share amounts)

(unaudited)

	FY 2008*	FY 2009*	FY 2010*	FY 2011*	FY 2012*
Consolidated Net sales	\$1,727,480	\$2,005,590	\$ 2,268,150	\$ 2,755,029	\$ 3,173,249
	ψ1,727,100	φ2,000,000	φ 2,200,100	φ 2,700,020	φ 0, 170,210
Reported operating income	\$ 192,759	\$ 249,488	\$ 335,899	\$ 490,205	\$ 569,226
Acquisition-related costs	-	-	8,189	3,243	9,381
Deal-related amortization <sup>(3)</sup>	24,218	23,596	25,127	46,778	74,793
Impairment of note receivable	-	-	-	-	-
Impairment of fixed assets	-	1,600	-	-	-
Impairment of intangible asset	10,346	-	-	-	-
Inventory step-ups	5,756	2,923	10,904	-	27,179
Loss on asset exchange	-	639	-	-	-
Restructuring charges	2,312	14,647	9,523	1,033	8,755
Net charge associated with acquired R&D and proceeds from sale of IPR&D projects	-	-	-	-	750
Earnings associated with sale of pipeline development projects	-	-	-	-	(3,500)
Write-offs of in-process R&D	2,786	279	19,000		-
Adjusted operating income	\$ 238,177	\$ 293,172	\$ 408,642	\$ 541,259	\$ 686,584
Adjusted operating income %	13.8%	14.6%	18.0%	19.6%	21.6%

\*All information based on continuing operations.





#### Table II PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES (in thousands)

(unaudited)

	FY 20	008*	FY	2009*	F	Y 2010*	F	Y 2011*	F	Y 2012*
Consumer Healthcare	¢4.40	0.404	<b>C</b> 4 4		<b>.</b> .	570 740	<b>.</b> .	004.000	<b>~</b> 4	045 700
Net sales	\$1,169	9,131	\$1,4	12,550	\$1	,573,749	\$1	,684,938	\$1	,815,788
Reported operating income	\$ 182	2,700	\$ 2	50,044	\$	313,689	\$	308,953	\$	315,302
Deal-related amortization <sup>(1)</sup>	ţ	5,314		6,647		5,898		8,387		9,312
Impairment of note receivable		-		-		-		-		-
Impairment of fixed assets		-		1,600		-		-		-
Inventory step-ups	Ę	5,756		1,861		468		-		-
Loss on asset exchange		-		639		-		-		-
Restructuring charges	-	2,312		-		-		1,033		-
Adjusted operating income	\$ 196	6,082	\$ 20	60,791	\$	320,055	\$	318,373	\$	324,614
Adjusted operating income %	1	16.8%		18.5%		20.3%		18.9%		17.9%
Rx Pharmaceuticals										
Net sales	\$ 159	9,576	\$ 10	63,947	\$	237,569	\$	343,717	\$	617,389
Reported operating income	\$ 20	0,243	\$ 2	24,481	\$	44,578	\$	114,636	\$	213,495
Deal-related amortization (1)	16	6,007		11,190		10,800		10,958		32,428
Impairment of intangible asset	1(	0,346		-		-		-		-
Inventory step-ups		-		-		-		-		27,179
Acquisition-related costs		-		-		-		-		3,755
Net charge associated with acquired R&D and proceeds from sale of IPR&D projects		-		-		-		-		750
Earnings associated with sale of pipeline development projects		-		-		-		-		(3,500)
Write-offs of in-process R&D	-			-		19,000		-		-
Adjusted operating income			\$ 3	35,671	\$	74,378	\$	125,594	\$	274,107
Adjusted operating income %	2	29.2%		21.8%		31.3%		36.5%		44.4%
API										
Net sales	\$ 144	4,444	\$ 13	35,731	\$	139,980	\$	155,717	\$	165,782
Reported operating income	\$ 13	3,881	\$	2,296	\$	13,688	\$	36,231	\$	53,882
Deal-related amortization <sup>(1)</sup>		2,260		2,187		1,967		2,503		1,989
Restructuring charges		-		14,647		8,824		-		-
Adjusted operating income	\$ 16	6,141	\$ <sup>·</sup>	19,130	\$	24,479	\$	38,734	\$	55,871
Adjusted operating income %	1	11.2%		14.1%		17.5%		24.9%		33.7%

(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions



\*All information based on continuing operations.



# Table IIIPERRIGO COMPANYFY 2012 GUIDANCERECONCILIATION OF NON-GAAP MEASURES

#### (unaudited)

	Full Year Fiscal 2013 Guidance		Full Year Fiscal 2013 Guidance
Consolidated		Nutritionals	
Reported consolidated gross margin range (2)	34% - 38%	Reported gross margin range	23.7% - 27.7%
Deal-related amortization (1,2)	1.8%	Deal-related amortization <sup>(1)</sup>	2.3%
Inventory step-up <sup>(2)</sup>	0.2%	Adjusted gross margin range	26% - 30%
Adjusted consolidated gross margin range	36% - 40%		
		Reported operating margin range	4.5% - 8.5%
Reported distribution, selling, general and administrative		Deal-related amortization <sup>(1)</sup>	5.5%
expense as % of net sales <sup>(2)</sup>	13.3%	Adjusted operating margin range	10% - 14%
Deal-related amortization (1,2)	-0.7%		
Acquisition and severance costs (2)	-0.1%	Rx Pharmaceuticals	
Adjusted distribution, selling, general and administrative		Reported gross margin range	48.6% - 53.6%
expense as % of net sales	12.5%	Deal-related amortization <sup>(1)</sup>	5.4%
		Adjusted gross margin range	54% - 59%
Reported consolidated operating margin range <sup>(2)</sup>	18.2% - 21.2%		
Deal-related amortization (1,2)	2.5%	Reported operating margin range	36.4% - 42.4%
Inventory step-up (2)	0.2%	Deal-related amortization <sup>(1)</sup>	5.4%
Acquisition and severance costs <sup>(2)</sup>	0.1%	Severance costs	0.2%
Adjusted consolidated operating margin range	21% - 24%	Adjusted operating margin range	42% - 48%
Consumer Healthcare		API	
Reported gross margin range <sup>(2)</sup>	31.1% - 35.1%	Reported gross margin range	45.8% - 50.8%
Deal-related amortization <sup>(1,2)</sup>	0.5%	Deal-related amortization <sup>(1)</sup>	1.2%
Inventory step-up (2)	0.4%	Adjusted gross margin range	47% - 52%
Adjusted gross margin range	32% - 36%		
		Reported operating margin range	25.8% - 30.8%
Reported operating margin range (2)	15.8% - 19.8%	Deal-related amortization <sup>(1)</sup>	1.2%
Deal-related amortization <sup>(1,2)</sup>	0.8%	Adjusted operating margin range	27% - 32%
Inventory step-up (2)	0.4%		
Adjusted operating margin range	17% - 21%	(1) Amortization of acquired intangible assets	s related to business combinations
, , , , , , , , , , , , , , , , , , , ,		and asset acquisitions	

(2) Does not include any estimate related to the Velcera acquisition



35

(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions

(2) Does not include any estimate related to the Velcera acquisition



# Table IV PERRIGO COMPANY RECONCILIATION OF NON-GAAP MEASURES (dollars in thousands) (unaudited)

	Fiscal Year						
		2009		2010		2011	 2012
Net cash from operating activities Changes in operating assets and liabilities, net of	\$	239,757	\$	332,363	\$	373,961	\$ 513,376
asset and business acquisitions and disposition		12,091		(19,226)		12,760	51,849
Other non-cash expenses		(35,018)		(15,234)		55,417	(28,289)
Interest expense, net		26,995		28,415		42,312	60,736
Income tax expense		63,452		84,215		109,996	119,015
EBITDA	\$	307,277	\$	410,533	\$	594,446	\$ 716,687

Total debt, including current maturities

Debt to EBITDA

\$ 1,369,325

1.91





#### Table V PERRIGO COMPANY FY 2013 GUIDANCE AND FY 2012 EPS RECONCILIATION OF NON-GAAP MEASURES (unaudited)

	Cobrek Full Year Fiscal 2013 Guidance
FY13 reported diluted EPS contribution related to Cobrek acquisition	(\$0.01)
Deal-related amortization <sup>(1)</sup>	0.02
Loss on sale of investment	0.02
Charge associated with severance costs	0.01
FY13 adjusted diluted EPS contribution related to Cobrek acquisition	\$0.04

	Sergeant's & Velcera Full Year Fiscal 2014 Guidance
FY14 reported diluted EPS contribution related to Sergeant's and Velcera acquisitions <sup>(2)</sup>	\$0.09 - \$0.13
Intangible amortization, transaction and integration-related costs	0.18 - 0.22
FY14 adjusted diluted EPS contribution related to Sergeant's and Velcera acquisitions	\$0.31
	First 12 Months Accretion Post-Closing Rosemont
Rosemont accretion first 12 months post-close - reported diluted EPS	\$0.02
Deal-related amortization <sup>(1)</sup>	0.13
Charge associated with inventory step-up	0.06
Charges associated with acquisition-related costs	0.03
Rosemont accretion first 12 months post-close - adjusted diluted EPS	\$0.24

(1) Amortization of acquired intangible assets related to business combinations and asset acquisitions

(2) Assuming a full twelve months of Velcera results in fiscal 2014



. . . . . . . . . . . . .